We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Madrigal Pharmaceutical’s investigational drug resmetirom reduced liver fat by up to 48 percent over one year, raising hopes of a first-in-class approval for nonalcoholic steatohepatitis (NASH), company executives said yesterday. Read More
Protection against Omicron-related death in people 50 and older reached as high as 95 percent after a booster dose of a messenger RNA (mRNA) vaccine, the UK Health Security Agency (UKHSA) announced Thursday. Read More
Merck’s Keytruda (pembrolizumab) has made a couple of headlines this week, drawing attention as a potential weapon against latent HIV infections, and winning approval in Europe as a kidney cancer monotherapy. Read More
Sierra Oncology has announced that its experimental blood cancer treatment has reached all primary and key secondary endpoints in a phase 3 study, including maintaining platelet counts. Read More
Both studies are in line with real-world data released by the Centers for Disease Control and Prevention last week showing that a third dose of vaccine from Pfizer/BioNTech or Moderna slashed Omicron-related COVID-19 hospitalizations by 90 percent. Read More
Sanofi is partnering with Protas, a new UK-based nonprofit organization masterminded by Martin Landray, the leader of the UK’s lauded and highly successful RECOVERY trial, which evaluated multiple treatments for COVID-19. Read More